Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Piper Sandler Analyst Says

Ionis Pharmaceuticals (NASDAQ:IONS) had its target price upped by equities researchers at Piper Sandler from $87.00 to $100.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target would indicate a potential upside of 23.23% from the company’s current price.

A number of other research firms have also recently commented on IONS. Needham & Company LLC raised their target price on shares of Ionis Pharmaceuticals from $90.00 to $103.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Thursday, January 22nd. Leerink Partners raised their price objective on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Bank of America lifted their target price on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $88.80.

Ionis Pharmaceuticals Price Performance

NASDAQ IONS opened at $81.15 on Friday. The business’s fifty day moving average is $81.33 and its 200 day moving average is $72.12. Ionis Pharmaceuticals has a fifty-two week low of $23.95 and a fifty-two week high of $86.74. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. The company has a market capitalization of $13.14 billion, a PE ratio of -33.26 and a beta of 0.29.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). Ionis Pharmaceuticals had a negative return on equity of 66.25% and a negative net margin of 40.36%.The company had revenue of $203.00 million during the quarter, compared to analysts’ expectations of $156.07 million. During the same quarter in the previous year, the company earned ($0.66) EPS. The business’s quarterly revenue was down 10.6% compared to the same quarter last year. Sell-side analysts predict that Ionis Pharmaceuticals will post -3.5 earnings per share for the current year.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Eric Swayze sold 23,463 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $79.12, for a total value of $1,856,392.56. Following the completion of the transaction, the executive vice president directly owned 30,453 shares of the company’s stock, valued at approximately $2,409,441.36. This trade represents a 43.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Shannon L. Devers sold 44,199 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $85.08, for a total transaction of $3,760,450.92. Following the completion of the sale, the executive vice president owned 17,494 shares in the company, valued at $1,488,389.52. This represents a 71.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 464,579 shares of company stock valued at $37,630,193 in the last 90 days. 2.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Brown Brothers Harriman & Co. purchased a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at about $27,000. Golden State Wealth Management LLC grew its position in Ionis Pharmaceuticals by 198.4% in the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after acquiring an additional 250 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Ionis Pharmaceuticals during the third quarter worth approximately $25,000. Mather Group LLC. purchased a new stake in Ionis Pharmaceuticals during the third quarter valued at approximately $27,000. Finally, Quarry LP purchased a new stake in Ionis Pharmaceuticals during the third quarter valued at approximately $38,000. 93.86% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Piper Sandler raised its price target to $100 and moved to an “overweight” rating, signaling ~23% upside from current levels — a clear buy-side endorsement. Article Title
• Positive Sentiment: Needham lifted its price target to $103 from $90, another analyst upgrade supporting the rally and reflecting greater confidence in revenue trajectory. Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
• Positive Sentiment: Updates to Tryngolza outlook are materially positive: recent analysis lifts peak revenue estimates (several sources cite >$2B for Tryngolza and company-level peak revenue/royalty/milestone potential in the multi‑billion range), and management guides to cash-flow breakeven by 2028 — bullish for long-term value. Ionis Pharmaceuticals: Digesting Recent Events
• Neutral Sentiment: Company presented at Oppenheimer’s healthcare conference; slides/transcript provide additional visibility into pipeline progress and commercialization strategy but are informational rather than catalytic. IONS Presents at Oppenheimer Conference Transcript
• Neutral Sentiment: General earnings call coverage/recaps are available for detail on management commentary and guidance; useful for modeling but not single-handedly market-moving. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 results were mixed: revenue and Tryngolza sales beat expectations, but EPS missed estimates and management gave a softer 2026 outlook, which pressured the stock in after-hours/early trade. Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
• Negative Sentiment: Coverage noted the EPS miss led to a gap-down reaction in some sessions; near-term uptake for new drugs and the FY2026 revenue cadence remain the main risk factors to watch. Shares Gap Down on Disappointing Earnings
• Negative Sentiment: Stifel raised its target modestly to $77 but kept a “hold” rating — the lower relative PT signals at least one shop sees limited near-term upside. Article Title

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.